In addition to small molecule chemotherapy agents, using targeted drug therapy is another attractive approach and several monoclonal antibodies are being used in treating CLL including rituximab (Rituxan, directed against CD20), alemtuzumab (Campath, directed against CD52) and ofatumumab (Arzerra, directed against CD20). Here, CD52 is linked to B-cell chronic lymphocytic leukemia.